ImpediMed Ltd. | Mutual Funds
Mutual Funds that own ImpediMed Ltd.
Fidelity Funds SICAV - Pacific Fund
18,461,243
4.87%
-7,706
0.26%
05/31/2018
Allan Gray Australia Equity Fund
16,854,234
4.45%
16,854,234
0.51%
12/31/2017
Vanguard Australian Shares Index Fund
2,614,894
0.69%
292,689
0.01%
07/31/2018
Fidelity Japan Japan/Asia Growth Equity Mother Fund
733,230
0.19%
19,438
0.49%
12/11/2017
NEF - Azionario Pacifico
707,818
0.19%
43,047
0.25%
12/31/2017
BlackRock Wholesale Indexed Australian Equity Fund
420,533
0.11%
0
0.01%
07/31/2018
Barclays MM Fd. Plc - GlobalAccess Pacific Rim (ex Japan) Fund
260,300
0.07%
100,040
0.07%
11/30/2017
Fidelity Funds SICAV - FAWF Pacific Fund
249,577
0.07%
-7,155
0.24%
10/31/2017
iShares S&P ASX Small Ordinaries ETF
204,542
0.05%
6,064
0.09%
06/29/2018
Fidelity Funds SICAV - FAWF International Fund
0
0%
-448
0%
10/31/2017
| Address |
50 Parker Court
Pinkenba Queensland (QLD) 4008
Australia
|
|
Employees
|
- |
| Website |
http://www.impedimed.com |
| Updated |
07/08/2019 |
| ImpediMed Ltd. engages in the development and distribution of medical devices using bioimpedance spectroscopy technologies for use in the non-invasive clinical assessment and monitoring of human disorders and diseases. It operates through the Medical and Test and Measurement segments. The Medical segment supplies non-invasive medical devices to two under-served markets: aiding in the subclinical assessment of individuals at risk of secondary lymphoedema; and the monitoring of body composition and hydration. |
